Global pulmonary drug delivery systems market was valued at $49782.76 million in 2020, and is estimated to reach $ 91,128.61 million by 2030, growing at a CAGR of 6.08% from 2021 to 2030.
The term “targeted drug delivery” refers to directing the drug toward the targeted site. Pulmonary drug delivery is a type of targeted drug delivery system in which the drug moiety is directed toward the lower respiratory tract. The pulmonary drug delivery system refers to a device used to infuse drugs into the body through the pulmonary route. The inhalation route provides a better alternative for drug delivery for the treatment of asthma and chronic obstructive pulmonary disease. Pulmonary drug delivery provides immediate action which gives quick relief from asthmatic attacks and acute bronchitis. Aerosols are a particularly designed device, used for pulmonary drug delivery.
The global pulmonary drug delivery systems market is being driven primarily by an increase in air pollution, rise in prevalence of pulmonary diseases, such as asthma and chronic obstructive pulmonary disease; increase in number of hospitals & diagnostic centers; surge in funding from private & government organizations for treatment of pulmonary diseases and rise in awareness regarding pulmonary health. According to World Health Organization (WHO), 9 out of 10 people breathe air that contains high levels of pollutants and estimates show an alarming death toll of 7 million people every year caused by ambient (outdoor) and household air pollution in 2018
Furthermore, there is an increase in prevalence of chronic obstructive pulmonary diseases. It is a group of respiratory tract disease in which there is inflammation of lugs resulting in obstructive air flow. According to WHO, “Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death globally, which caused 3.23 million deaths in 2019.”
Moreover, development in pulmonary drug delivery systems is anticipated to contribute toward the growth of the market. For instance, in October 2018, Philips, a global leader in health technology, launched InnoSpire Go; a potable mesh nebulizer which is small in size ,light in weight, and easily portable hand-held nebulizer system designed to deliver drug in just four minutes. Furthermore, the rise in awareness among individuals for management & treatment of pulmonary diseases and rise in number of hospitals & diagnostic centers are expected to provide remunerative opportunities for the expansion of the global pulmonary drug delivery system market during the forecast period. Moreover, the presence of key manufacturing companies in pulmonary drug delivery system and advancement in the treatment for pulmonary diseases propel the growth of the market.
Thus, the presence of various healthcare foundations and government initiatives for the treatment of pulmonary diseases propel the growth of the market. However, high prices associated with pulmonary drug delivery system devices and inaccurate diagnosis of respiratory diseases restrict the market growth during the forecast period.
Global Pulmonary Drug Delivery Systems Market Segmentation
The global pulmonary drug delivery systems market is segmented into product, application, and distribution channel. On the basis of the product, the market is categorized into dry powder inhaler, metered dose inhaler, and nebulizers.
On the basis of application, it is divided into asthma, chronic obstructive pulmonary diseases, and cystic fibrosis. On the basis of distribution channel, it is categorized into retail pharmacies, hospital pharmacies, and e-commerce.
By Product
Metered dose inhaler segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
On the basis of product, the metered dose inhaler segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to advancement in pulmonary drug delivery treatment, increase in number of hospitals & diagnostic centers, and surge in awareness regarding pulmonary healthcare. However, the dry powder inhalers segment is expected to grow significantly during the forecast period, owing to latest developments in pulmonary drug delivery devices.
By Application
Asthma segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
By application, the asthma segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in air pollution leading to pulmonary diseases, and increase in number of hospitals and diagnostic centers. However, the Chronic Obstructive Pulmonary Disease (COPD) segment is expected to witness considerable growth during the forecast period, due to increase in diagnosis of pulmonary diseases and rise in smoking culture results in chronic bronchitis.
On the basis of distribution channel, the retail pharmacies segment dominated the market in 2020 and is expected to continue to dominate during the forecast period, owing to increase in retail pharmacies, rise in prevalence of pulmonary diseases, and development in R&D activities for lymphoma cancer treatment. However, the e-commerce segment is expected to witness considerable growth during the forecast period, owing to an increase in the number of internet users.
By Disrtribution Channel
Retail pharmacies segment is projected as one of the most lucrative segment.
North America dominated the pulmonary drug delivery systems market in 2020 and is anticipated to remain dominant during the forecast period, owing to an increase in the prevalence of pulmonary diseases, presence of key players for manufacturing & developing drugs for pulmonary diseases, increase in number of hospitals & diagnostic centers and initiatives taken by government for pulmonary disease treatment in the region. However, Asia-Pacific is expected to register the highest CAGR of 7.1% from 2021 to 2030, owing to increase in prevalence of pulmonary diseases, rise in demand for pulmonary drug delivery, and presence of various healthcare foundations.
The key players operating in the global pulmonary drug delivery systems market include AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG, Koninklijke Philips N.V., 3M Company, Actelion Pharmaceuticals Ltd (Janssen), Clement, Clarke International, Briggs Healthcare and Aerogen
By Region
North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the pulmonary drug delivery systems market, and the current trends & future estimations to elucidate imminent investment pockets.
- It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
- Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Pulmonary Drug Delivery Systems Market Report Highlights
| Aspects | Details |
 By Product |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 By Key Market Players |
|
Analyst Review
The global pulmonary drug delivery system is a form of targeting in which the drug in the form of dispersed particles is inhaled with aerosol. Pulmonary drug delivery system provides immediate relief in the management of Asthma and COPD.
The factors such as rise in pollution and smoking habit in population, surge in approach for alternative drug delivery options, and increase in number of hospitals are expected to drive the growth of the pulmonary drug delivery system market. Moreover, the method for prophylaxis and treatment of COVID-19, further boost the growth of the market. However, improper diagnosis and formulation stability problems hamper the market growth.
North America is expected to experience the highest growth, in terms of revenue, owing to rise in the prevalence of pulmonary diseases, the presence of key players for manufacturing & developing drugs for pulmonary diseases, increase in number of hospitals & diagnostic centers, and initiatives taken by government for pulmonary disease treatment in the region.
Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register the fastest CAGR during the forecast period, owing to an increase in the prevalence of pulmonary disease, rise in the awareness regarding health, and presence of various healthcare foundations.
However, improper diagnosis of pulmonary disease and high price associated with pulmonary drug delivery devices are anticipated to restrain the market growth during the forecast period.
The total market value of pulmonary drug delivery systems market is $49782.76 million in 2020.
The forecast period in the report is from 2021 to 2030
The market value of pulmonary drug delivery systems Market in 2021 is $ 53,566.25 million
The base year for the report is 2020.
Yes, pulmonary drug delivery systems companies are profiled in the report
The top companies that hold the market share in pulmonary drug delivery systems market are AstraZeneca plc, Boehringer Ingelheim Gmbh, GlaxoSmithKline plc, Novartis AG, Koninklijke Philips N.V., 3M company, Janssen (Johnson & Johnson), Clement, Clarke International, Briggs Healthcare and Aerogen
Asia-Pacific is expected to register the highest CAGR of 7.1% from 2021 to 2030, owing to increase in prevalence of pulmonary diseases, technical advancements in pulmonary drug delivery systems, and government initiatives for treatment of pulmonary disease.
The key trends in thepulmonary drug delivery systems market are by an increase in the prevalence of pulmonary diseases, such as asthma, chronic pulmonary drug delivery systems, & cystic fibrosis, advancement in pulmonary drug delivery systems; government initiatives for treatment of pulmonary drug delivery systems.
Loading Table Of Content...
